Insights derived from analysing SEC filings. Independent analysis, not a publication of the SEC. Revenue is below $1m a quarter, so margins on revenue run into thousands of %; the margin lines in Figures 1.1 and 2.1 show this scale only, and Table 1.1 and Figure 2.4 give costs and losses in $m.
Figures are read from the filings of NuScale Power Corporation (central index key 1822966): the Q3 2026 results release (8-K Item 2.02, Ex 99.1 of 5 Nov 2026) and the Q3 2026 Form 10-Q of the same day, the Forms 10-K for FY2022 to FY2025, the Forms 10-Q for Q1 2025 to Q2 2026, the Forms 8-K with all their exhibits, incl. the results releases for FY2025 to Q2 2026, the ATM sales agreements and the Item 5.07 vote results, the 2026 proxy statement, Fluor's Schedules 13D/A and Forms 4, Schedules 13G and the Forms 4 of officers and directors, and the Forms 10-Q and 10-K of Oklo, NANO Nuclear Energy, BWX Technologies and GE Vernova used in chapters 2 to 4 and 7. NuScale files no separate CFO commentary document, so CFO figures come from the financial update in the releases; earnings call remarks are left out. Share price $4.66 is the regular session close of 13 Nov 2026. Accession numbers appear in the Sources appendix.
| Line ($m unless stated) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 13.38 | 8.05 | 8.24 | 1.81 | 0.57 | 0.08 | 0.28 |
| of which from Fluor (related party) | 7.27 | 7.43 | 7.87 | 1.35 | 0.00 | 0.00 | 0.00 |
| Cost of sales | 6.37 | 6.27 | 5.53 | 1.87 | 0.54 | 0.23 | 0.15 |
| Research and development | 9.1 | 11.8 | 11.1 | 13.5 | 12.8 | 18.4 | 18.0 |
| General and administrative | 23.3 | 22.5 | 519.2 | 44.8 | 24.8 | 26.9 | 27.9 |
| Other expenses | 9.9 | 10.5 | 10.9 | 14.3 | 19.9 | 18.5 | 19.0 |
| Operating loss | (35.3) | (43.1) | (538.4) | (72.7) | (57.5) | (64.0) | (64.8) |
| Investment income | 5.2 | 5.5 | 5.8 | 8.9 | 10.8 | 13.9 | 19.1 |
| Net loss incl. noncontrolling interests | (30.4) | (37.6) | (532.6) | (63.8) | (46.7) | (50.1) | (45.7) |
| Net loss to Class A stockholders | (14.0) | (17.6) | (273.3) | (50.8) | (44.0) | (47.5) | (43.7) |
| Loss per Class A share ($) | (0.11) | (0.13) | (1.85) | n/a | (0.14) | (0.13) | (0.11) |
| Operating cash flow | (22.8) | (33.3) | (199.8) | (203.7) | (314.7) | (58.2) | (28.6) |
| Capital expenditure | (0.07) | 0.00 | (0.07) | (0.37) | (1.52) | (0.43) | (0.09) |
| Equity raised, net | 99.8 | 0.0 | 462.6 | 737.4 | 37.3 | 947.2 | 0.0 |
| Cash and investments, quarter end | 521.4 | 489.9 | 753.8 | 1,287.2 | 1,008.8 | 1,893.0 | 1,864.1 |
| Long lead material work in process, quarter end | 45.0 | 64.3 | 63.3 | 63.8 | 65.1 | 68.6 | 69.7 |
| Company | Line | Period | Value | Growth (%) | Margin (%) | Detail |
|---|---|---|---|---|---|---|
| NuScale Power | Revenue | Q3 2026 | $0.28m | (96.6) | n/a | operating loss $64.8m; cash and investments $1.86bn |
| Oklo | Revenue | Q3 2026 | $1.86m | n/a | n/a | operating loss $71.0m; cash and debt securities $3.13bn |
| NANO Nuclear Energy | Revenue | Jun 2026 quarter | $0.21m | n/a | n/a | operating loss $15.8m; KRONOS construction permit application accepted 18 May 2026 |
| Company | Line | Period | Value | Growth (%) | Margin (%) | Detail |
|---|---|---|---|---|---|---|
| NuScale Power | Revenue | 9M 2026 | $0.92m | (96.9) | n/a | RoPower FEED Phase 2 ended late 2025; E2 Centers $0.59m |
| GE Vernova | Revenue | Q3 2026 | $12.64bn | 26.8 | 11.0 | Power segment covers gas, nuclear and hydro; RPO $196.7bn |
| Company | Line | Period | Value | Growth (%) | Margin (%) | Detail |
|---|---|---|---|---|---|---|
| NuScale Power | R&D expense | Q3 2026 | $18.0m | 62.9 | n/a | LLM work in process $69.7m; commitments $169.8m |
| BWX Technologies | Revenue | Q3 2026 | $953.0m | 10.0 | 13.9 | RPO $8.56bn; Commercial Operations makes steam generators and reactor components |
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM Q3 2026 |
|---|---|---|---|---|---|---|
| Revenue | 2.9 | 11.8 | 22.8 | 37.0 | 31.5 | 2.7 |
| Gross profit | 1.1 | 4.5 | 3.8 | 32.1 | 11.4 | (0.1) |
| Research and development | 93.1 | 123.4 | 156.1 | 46.8 | 45.5 | 62.8 |
| Selling, general and administrative | 45.2 | 63.1 | 65.4 | 75.9 | 609.8 | 124.4 |
| Operating income | (174.3) | (230.0) | (275.6) | (138.7) | (689.6) | (259.1) |
| Net income | (102.5) | (141.6) | (180.1) | (348.4) | (664.5) | (206.3) |
| Diluted EPS ($) | n/a | (0.51) | (0.80) | (1.47) | (2.17) | n/a |
| Operating cash flow | (99.2) | (148.6) | (183.3) | (108.7) | (459.6) | (605.1) |
| Capital expenditure | (2.0) | (2.3) | (1.7) | 0.0 | (0.5) | (2.4) |
| Free cash flow | (101.1) | (150.9) | (185.0) | (108.7) | (460.1) | (607.5) |
| Stock based compensation | 6.4 | 9.3 | 16.2 | 13.6 | 19.2 | 22.7 |
| Cash and investments | 77.1 | 267.7 | 120.3 | 441.6 | 1,287.2 | 1,864.1 |
| Total debt | 14.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total equity | 66.3 | 277.1 | 129.3 | 453.1 | 1,113.6 | 1,974.4 |
| Metric | Q3 2025 | Q3 2026 | Change |
|---|---|---|---|
| Revenue ($m) | 8.2 | 0.3 | (96.6%) |
| Gross profit ($m) | 2.7 | 0.1 | (95.1%) |
| Operating income ($m) | (538.4) | (64.8) | 88.0% |
| Net income ($m) | (532.6) | (45.7) | 91.4% |
| Diluted EPS ($) | (1.85) | (0.11) | 94.1% |
| Operating cash flow ($m) | (199.8) | (28.6) | 85.7% |
| Free cash flow ($m) | (199.9) | (28.7) | 85.7% |
| Operating margin (%) | (6,532.9) | (23,067.6) | (16,534.7 pts) |
| Net margin (%) | (6,462.6) | (16,266.5) | (9,804.0 pts) |
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM Q3 2026 |
|---|---|---|---|---|---|---|
| Growth and margins | ||||||
| Revenue growth (%) | n/a | 312.4 | 93.2 | 62.4 | (15.0) | n/a |
| Gross margin (%) | 38.2 | 38.0 | 16.9 | 86.7 | 36.3 | (2.2) |
| Liquidity and leverage | ||||||
| Current ratio (x) | 1.78 | 7.38 | 1.77 | 5.25 | 4.30 | 24.40 |
| Net cash ($bn) | 0.1 | 0.3 | 0.1 | 0.4 | 1.3 | 1.9 |
| Measure | Value |
|---|---|
| Market cap ($bn) | 2.0 |
| Enterprise value ($bn) | 0.1 |
| FCF yield (%) | (30.3) |
| Price/Book (x) | 1.0 |
| Line ($m) | Q3 2025 | Q3 2026 | Change |
|---|---|---|---|
| Revenue | 8.24 | 0.28 | (96.6%) |
| Cost of sales | 5.53 | 0.15 | (97.3%) |
| Research and development | 11.1 | 18.0 | +62.9% |
| General and administrative | 519.2 | 27.9 | (94.6%) |
| Other expenses | 10.9 | 19.0 | +75.0% |
| Operating loss | (538.4) | (64.8) | (88.0%) |
| Investment income | 5.76 | 19.1 | +231.7% |
| Net loss incl. noncontrolling interests | (532.6) | (45.7) | (91.4%) |
| Net loss to Class A stockholders | (273.3) | (43.7) | (84.0%) |
| G&A excluding Milestone Contribution 1 (derived) | 24.2 | 27.9 | +15.3% |
| Costs excluding Milestone Contribution 1 (derived) | 51.7 | 65.1 | +26.0% |
| Labor costs (all expense lines) | 22.2 | 32.6 | +47.1% |
| Period | Program | Shares (m) | Gross proceeds ($m) | Average price ($) |
|---|---|---|---|---|
| 9M 2025 | 2025 ATM ($500m, Aug 2025) and a prior program | 17.8 | 577.6 | 33.68 |
| Q4 2025 | ATM program of 7 Nov 2025 | 39.3 | 750.0 | n/a |
| 9M 2026 | 2026 ATM ($1.0bn, Feb 2026), completed Jun 2026 | 89.7 | 1,000.0 | 11.14 |
| Q3 2026 | ATM of 11 Aug 2026 ($750m) | 0.0 | 0.0 | n/a |
| Item | Outlook | Source |
|---|---|---|
| Financial guidance | none given for revenue, costs or cash use in any 2026 release | 8-K Ex 99.1, 26 Feb, 7 May, 5 Aug and 5 Nov 2026 |
| TVA program | next phase of the ENTRA1 and TVA collaboration depends on one or more PPAs between ENTRA1 and TVA; NuScale is positioning to support it | 10-Q Q3 2026 MD&A |
| RoPower | no pre EPC contract expected until RoPower secures financing; NuScale expects to recommence work once one is signed | 10-Q Q3 2026 MD&A |
| Liquidity | sufficient for the next 12 months and beyond, with continued access to capital markets | 10-Q Q3 2026 MD&A |
| PMA payments | MC2 on a binding PPA, MC3 on an OEM agreement; criteria not met at 30 Sep 2026 | 10-Q Q3 2026 Note 9 |
| 2026 focus (Feb 2026) | commercialization and full readiness to manufacture the first NPM | 8-K Ex 99.1, 26 Feb 2026 |
| Speaker | Date and source | Statement |
|---|---|---|
| John Hopkins, CEO | 5 Nov 2026, 8-K Ex 99.1 | “physical production of our first commercial NuScale Power Module” |
| John Hopkins, CEO | 5 Aug 2026, 8-K Ex 99.1 | “that work is now substantially complete” |
| John Hopkins, CEO | 26 Feb 2026, 8-K Ex 99.1 | “ensuring full readiness for the manufacturing of our first NPM” |
| Item | Disclosure |
|---|---|
| 10-Q Q3 2026, Note 9 (PMA) | Milestone Contribution 1 for 72 NPMs cost $507.4m: $247.5m settled in 2025 and $259.9m in 9M 2026; no accrued PMA liability at 30 Sep 2026. |
| 10-Q Q3 2026, liquidity | Cash $513.4m, short term investments $420.0m, long term investments $930.7m, no debt; 89.7m shares sold in 9M 2026 for $1.0bn gross at $11.14 on average. |
| 10-Q Q3 2026, legal | Truedson class action (filed 18 Feb 2026, amended 10 Jul 2026) on statements about ENTRA1; motion to dismiss filed 25 Sep 2026; two derivative suits (24 Mar and 28 Oct 2026). |
| 10-Q Q3 2026, commitments | Cash commitments $169.8m, incl. $41.9m of LLM purchases due 2027, $43.5m under the ENTRA1 sales and marketing agreement and $25.8m of Paragon contracts (Jun 2026). |
| 10-Q Q3 2026, related party | Fluor divested all Class A shares and is no longer a related party; it supplied 96% of Q3 2025 revenue ($7.9m). |
| 10-K FY2025, Item 1 | Over $1.8bn invested in NuScale technology since 2007, incl. $578.3m from the DOE; 513 patents granted and 268 pending; 428 full time employees at 31 Dec 2025. |
| 10-K FY2025, Item 1 | NRC approved the 50 MWe 12 module design in Sep 2020 and the 77 MWe 6 module design (SDA) in May 2025; long lead items ordered from Doosan for the first twelve NPM upper reactor vessels. |
| 10-K FY2025, Item 1 | ENTRA1 holds exclusive worldwide commercialization rights under the Strategic Alliance Agreement effective 7 May 2025 and negotiates with TVA on up to six 12 module plants. |
| 10-K FY2025, Item 1A | No binding contract to deliver NPMs exists; initial deployment depends on RoPower and Fluor EPC, or an ENTRA1 PPA with a third party and an OEM agreement with NuScale. |
| Company | Revenue TTM ($bn) | Revenue growth (%) | Gross margin (%) | Operating margin (%) | Net margin (%) | FCF margin (%) | ROE (%) | Net cash ($bn) | Market value ($bn) | EV/Sales (x) | P/E TTM (x) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SMR | 0.0 | n/a | n/a | n/a | n/a | n/a | n/a | 1.9 | 2 | n/a | n/a |
| OKLO | 0.0 | n/a | n/a | n/a | n/a | n/a | n/a | 3.1 | 5 | n/a | n/a |
| BWXT | 3.6 | 10.0 | 22.6 | 12.4 | 10.4 | 10.3 | 28.3 | (1.5) | 11 | 3.5 | 30.1 |
| GEV | 44.0 | 26.8 | 21.7 | 6.4 | 23.5 | n/a | 91.9 | 13.9 | 213 | 4.5 | 20.5 |
| NNE | 0.0 | n/a | n/a | n/a | n/a | n/a | n/a | 0.6 | 1 | n/a | n/a |
| Company | Period | Revenue ($m) | Operating income ($m) | Free cash flow ($m) | Cash and investments ($m) | Market value ($bn) |
|---|---|---|---|---|---|---|
| NuScale Power (SMR) | TTM Q3 2026 | 2.7 | (259) | (608) | 1,864 | 2.00 |
| Oklo (OKLO) | TTM Q3 2026 | 3.1 | (252) | (452) | 3,131 | 4.67 |
| NANO Nuclear Energy (NNE) | TTM Jun 2026 quarter | 0.2 | (52) | (38) | 580 | 0.60 |
| BWX Technologies (BWXT) | TTM Q3 2026 | 3,600.7 | 445 | 372 | 569 | 11.27 |
| GE Vernova (GEV) | TTM Q3 2026 | 44,040.0 | 2,828 | n/a | 16,764 | 212.57 |
| Date | Items | Event |
|---|---|---|
| 17 Nov 2025 | 5.02, 5.03, 8.01 | David Tonnel appointed Chief Accounting Officer from 22 Nov 2025; bylaws amended to name the Chief Accounting Officer as an officer; deferred compensation plan for non employee directors adopted (Ex 3.1, Ex 10.1). |
| 17 Dec 2025 | 5.03, 5.07 | Special meeting of 16 Dec 2025 approved raising authorized Class A shares from 332,000,000 to 662,000,000: 184.5m for, 28.0m against, 0.6m abstain; certificate of amendment filed (Ex 3.1). |
| 27 Jan 2026 | 7.01 | Ex 99.1 announced the Q4 and FY2025 results call for 26 Feb 2026. |
| 26 Feb 2026 | 2.02 | FY2025 results (Ex 99.1): revenue $31.5m against $37.0m; G&A $609.8m incl. Milestone Contribution 1 of $507.4m to ENTRA1; net loss $664.5m; cash and investments $1.3bn; 39.3m shares sold under the ATM program in Q4 2025 for $750.0m gross. |
| 26 Feb 2026 | 1.01, 1.02 | New ATM sales agreement for up to $1.0bn of Class A stock with UBS, B. Riley, Canaccord and Tuohy Brothers, commission up to 2%; the 7 Nov 2025 ATM agreement terminated (Ex 1.1, 5.1, 23.1). |
| 8 Apr 2026 | 7.01 | Ex 99.1 announced the Q1 2026 results call for 7 May 2026. |
| 7 May 2026 | 2.02 | Q1 2026 results (Ex 99.1): revenue $0.6m against $13.4m; net loss $46.7m; operating cash use $314.7m incl. the $259.9m ENTRA1 payment; liquidity $1.0bn; Nuclearelectrica shareholders approved the next RoPower phase; Framatome fuel partnership expanded. |
| 2 Jun 2026 | 5.07 | Annual meeting of 29 May 2026: nine directors elected (Kimberly Warnica 78.9m for, 36.9m withheld; Stuart Harshaw 83.7m for, 32.1m withheld); say on pay 110.8m for, 4.2m against; Ernst & Young ratified. |
| 5 Aug 2026 | 2.02 | Q2 2026 results (Ex 99.1): revenue $0.1m against $8.1m; net loss $50.1m; liquidity $1.9bn after the $1.0bn ATM program completed in Jun 2026; Paragon awarded the HIPS final design contract. |
| 11 Aug 2026 | 1.01 | New ATM sales agreement for up to $750m of Class A stock with UBS, B. Riley, Canaccord, Craig‑Hallum, Texas Capital Securities and Tuohy Brothers, commission up to 2% (Ex 1.1, 5.1); no sales in Q3 2026 (10-Q). |
| 5 Nov 2026 | 2.02 | Q3 2026 results (Ex 99.1): revenue $0.3m against $8.2m; G&A $27.9m against $519.2m; net loss $45.7m; cash and investments $1.9bn; Doosan contract for the upper reactor coolant system of the first NPM. |
| Contract | Terms |
|---|---|
| Partnership Milestones Agreement with ENTRA1 (27 Aug 2025) | NuScale named key supplier for ENTRA1 Energy Projects to 31 Dec 2045 (renews for 20 years); contributions per NPM in three tranches of 15%, 35% and 50%; MC1 $507.4m for 72 NPMs paid; negotiated maximum NPM sale price; NuScale Corp guarantees NuScale LLC's obligations. |
| Strategic Alliance Agreement with ENTRA1 (amended and restated, 7 May 2025) | ENTRA1 holds exclusive worldwide rights to commercialize NuScale products and plants; NuScale needs ENTRA1 consent to pursue opportunities without it (10-K and 10-Q). |
| Sales and marketing agreement with ENTRA1 (2023, amended 1 Jan 2025) | $34.8m a year; renews annually unless terminated on six months' notice; $8.7m due in Q4 2026 and $34.8m in 2027. |
| ATM sales agreement of 26 Feb 2026 | up to $1.0bn; completed Jun 2026 with 89.7m shares at $11.14 on average; commission up to 2%. |
| ATM sales agreement of 11 Aug 2026 | up to $750m via UBS, B. Riley, Canaccord, Craig‑Hallum, Texas Capital Securities and Tuohy Brothers; no sales in Q3 2026. |
| Doosan Enerbility contracts | orders for long lead items for the first twelve NPM upper reactor vessels (10-K); LLM sourced from Doosan $69.7m in work in process at 30 Sep 2026; LLM materials purchase commitments $41.9m due 2027; Oct 2026 contract for fabrication of the upper reactor coolant system. |
| Paragon Energy Solutions (Jun 2026) | supply chain readiness and design contracts totaling $25.8m for the Highly Integrated Protection System. |
| Tax Receivable Agreement amendment with Fluor (6 Nov 2025) | payments due to Fluor under the 2022 TRA cut by 50%, alongside Fluor's exchange of 110,936,472 units into Class A shares (Schedule 13D/A no. 6). |
| Proposal | For (m votes) | Against (m votes) | Abstain (m votes) | For as % of votes cast | Result |
|---|---|---|---|---|---|
| Elect John L. Hopkins (CEO) | 114.4 | 1.5 | n/a | 98.7 | Elected |
| Elect Alan L. Boeckmann (chair) | 107.6 | 8.3 | n/a | 92.9 | Elected |
| Elect Stuart Harshaw | 83.7 | 32.1 | n/a | 72.3 | Elected |
| Elect Kimberly O. Warnica | 78.9 | 36.9 | n/a | 68.1 | Elected |
| Say on pay (advisory) | 110.8 | 4.2 | 0.8 | 96.3 | Approved |
| Ratify Ernst & Young for FY2026 | 193.6 | 2.3 | 1.0 | 98.8 | Approved |
| Holder | Source | Shares | Share of class |
|---|---|---|---|
| Van Eck Associates | Schedule 13G/A, 30 Sep 2026 | 28,046,447 | 6.8% of Class A |
| BlackRock | Schedule 13G, 30 Jun 2026 | 22,370,714 | 6.5% of Class A |
| Vanguard Capital Management | Schedule 13G, 30 Sep 2026 | 21,577,448 | 5.25% of Class A |
| Japan NuScale Innovation (JGC, IHI, Chubu, JBIC) | 2026 proxy (30 Mar 2026) | 19,285,070 Class B | 5.71% of voting power |
| Directors and executive officers (13) | 2026 proxy (30 Mar 2026) | 4,159,704 | 1.28% of Class A |
| Fluor | Forms 4, Feb to Apr 2026 | 0 | exited |
| Class A and Class B outstanding, 30 Oct 2026 | 10-Q Q3 2026 cover | 410,568,229 and 19,332,018 | 100% |
| Date | Event | Source |
|---|---|---|
| 7 Nov 2025 | Exchanged 110,936,472 NuScale LLC Class B units into Class A shares; TRA payments due to Fluor cut by 50% | Schedule 13D/A no. 6, filed 10 Nov 2025 |
| 9 Nov 2025 | Letter agreement to sell 71,000,000 shares to Goldman Sachs International at a variable price | Schedule 13D/A no. 6 |
| 13 Feb 2026 | 71,000,000 shares sold to Goldman Sachs at $19.0498 | Form 4; Schedule 13D/A no. 7 |
| 17 Feb 2026 | Agreements to sell 13,500,000 + 13,500,000 shares to Bank of America and 12,936,472 to Citibank; 40,400,219 shares held after the GS sale (13.3%) | Schedule 13D/A no. 7 |
| 26 Feb 2026 | 463,747 shares sold at $13.1466 | Form 4 |
| 9 Apr 2026 | 13,500,000 shares sold at $12.0665 | Form 4 |
| 15 Apr 2026 | 12,936,472 shares sold at $11.6293 | Form 4 |
| 21 Apr 2026 | 13,500,000 shares sold at $11.8092 | Form 4 |
| Person | Shares sold | Value ($m) |
|---|---|---|
| Robert Ramsey Hamady, CFO | 148,450 | 1.95 |
| Carl Fisher, COO | 90,245 | 1.07 |
| John Hopkins, CEO | 82,667 | 1.01 |
| Jose Reyes, CTO | 25,951 | 0.32 |
| Clayton Scott, CCO | 22,478 | 0.28 |
| Shinji Fujino, director | 20,000 | 0.18 |
| David Tonnel, CAO | 2,290 | 0.03 |
| Risk | Disclosure and change |
|---|---|
| No binding NPM contract | Initial deployment depends on RoPower and a Fluor EPC contract, or on an ENTRA1 PPA with a third party plus an OEM agreement with NuScale; neither existed at 5 Nov 2026. |
| PMA cash outlays (new) | MC1 cost $507.4m for 72 NPMs; MC2 (35%) falls due on a binding PPA and MC3 (50%) on an OEM agreement; this report derives about $1.18bn and $1.69bn for the same NPMs from the filed 15% share, amounts the filings do not state. |
| Dependence on ENTRA1 | ENTRA1 holds exclusive worldwide rights and decides in its sole discretion whether to buy from NuScale; the factor grew from 233 to 381 words. |
| Funding and dilution | Class A plus Class B shares rose from 337.9m at 31 Dec 2025 to 429.9m at 30 Sep 2026; authorized Class A doubled to 662m; a $750m ATM program is open. |
| Litigation | Truedson class action (filed 18 Feb 2026, amended 10 Jul 2026; class period 3 Mar to 6 Nov 2025) alleges misleading statements on ENTRA1's experience, qualifications and capabilities and Section 20A claims against Fluor; motion to dismiss filed 25 Sep 2026, opposition due 16 Nov 2026; derivative suits of 24 Mar 2026 (stayed) and 28 Oct 2026; no loss estimate. |
| Supply base and tariffs | If firm supplier orders are delayed, NuScale may lose manufacturing slots; long lead components are manufactured overseas, so US tariffs on them would raise costs (new factor). |
| Competition | Commercial SMRs operate in China and Russia; other designs hold NRC construction permits and are under construction (10-K FY2025). |
| Measure | 10-K FY2024 | 10-K FY2025 |
|---|---|---|
| Risk factors (count) | 45 | 40 |
| Words in Item 1A | 12,195 | 11,807 |
| Change | Risk factor | What changed |
|---|---|---|
| Added | PMA with ENTRA1: cash outlays without revenue | New factor: Milestone Contribution 1 for 72 NPMs cost about $507m; MC2 is due on a binding PPA and MC3 on an OEM agreement; contributions are unrecoverable if ENTRA1 generates no projects. |
| Added | US trade policy and tariffs | New factor: long lead components are made overseas, so tariffs on imports raise costs; retaliatory tariffs may hurt exports. |
| Added | No cash dividends expected | New factor: earnings retained to fund the business. |
| Removed | SDA applications may not be approved | Removed after the NRC approved the 77 MWe SDA in May 2025. |
| Removed | Material weakness in internal control | Removed; the FY2024 factor described an identified material weakness. |
| Removed | Raw material availability and costs | Its tariff and trade content moved into the new US trade policy factor; supply content into the constrained supply base factor. |
| Removed | Exercisable NuScale options and dilution | Removed as a separate factor. |
| Removed | NYSE listing and trading limits | Removed. |
| Removed | Tax law changes | Removed as a separate factor. |
| Removed | Changing laws on governance and disclosure | Removed. |
| Removed | Securities litigation | Merged into the general litigation factor, which now names the class action on ENTRA1 statements. |
| Reworded | Reliance on ENTRA1, Fluor and partners | Text grows from 233 to 381 words; ENTRA1 now listed first with exclusive worldwide rights under the Strategic Alliance Agreement of 7 May 2025, which restricts NuScale from contacting ENTRA1 relationships. |
| Reworded | No binding NPM contract | Initial deployment now tied to RoPower and a Fluor EPC contract, or an ENTRA1 PPA with a third party and an OEM agreement with NuScale. |
| Reworded | Competition from other technologies | Heading broadened from China and Russia SMRs to all reactor technologies; adds that other designs hold NRC construction permits and are under construction. |
| Reworded | Constrained supply base | Rewritten: until a binding NPM contract exists, suppliers may give slots to others, gain pricing power or become less responsive. |
| Reworded | Need for additional funding | Adds that financing may not be available on acceptable terms and that equity raises dilute holders. |
| Reworded | Evolving laws and regulations | Text grows from 162 to 299 words; adds the 2024 Loper Bright decision ending Chevron deference. |
| Reworded | Managing growth | Shortened from 173 to 77 words; refers to finding locations or partners to expand NPM manufacture. |
| Reworded | Litigation | Now names the class action in the District of Oregon on statements about ENTRA1 and states that a loss would be material. |
| Reworded | Public health crises | Rewritten in general terms. |
| Reworded | Delays in NPM development | Expanded from 161 to 229 words. |
| Filing | Change disclosed |
|---|---|
| 10-Q Q1 2026 filed 7 May 2026 | No material changes from the FY2025 10-K. |
| 10-Q Q2 2026 filed 5 Aug 2026 | No material changes from the FY2025 10-K. |
| 10-Q Q3 2026 filed 5 Nov 2026 | No material changes from the FY2025 10-K. |
| Factor | Current value | Best case requires | Evidence in filings |
|---|---|---|---|
| Binding PPA between ENTRA1 and TVA | non binding agreement for up to 6 GW (2 Sep 2025); no PPA at 5 Nov 2026 | PPA in 2027 and an OEM agreement for NPMs | 10-Q Q3 2026 MD&A and Note 9 |
| Funding of MC2 and MC3 | about $1.18bn and $1.69bn for 72 NPMs (this report's derivation from the 15% share; not filed) against cash of $1.86bn | payments matched by NPM order proceeds and equity at higher prices | 10-Q Q3 2026 Note 9 |
| First NPM fabrication | Doosan contract for the upper reactor coolant system (Oct 2026); LLM $69.7m | first module delivered on schedule and cost | 8-K Ex 99.1, 5 Nov 2026; 10-Q Note 7 |
| RoPower financing | Romanian investment decision approved 12 Feb 2026; pre EPC contract awaits financing | pre EPC contract and long lead orders in 2027 | 10-Q Q3 2026 MD&A |
| Cash use | 9M 2026 operating cash use $141.5m excl. MC1 (derived); investment income $19.1m in Q3 2026 | cash use held near $189m a year | 8-K Ex 99.1 cash flow statements |
| Litigation over ENTRA1 statements | class action and two derivative suits pending | dismissal without material loss | 10-Q Q3 2026 Note 13 |
| Measure | Worst case | Base case | Best case |
|---|---|---|---|
| Revenue CAGR, 3 years (%) | 54.2 | 350.8 | 719.1 |
| Revenue, TTM Q3 2029 ($bn) | 0.0 | 0.3 | 1.5 |
| Exit EV/Sales (x) | 3.0 | 5.0 | 4.0 |
| Implied price ($) | 2.81 | 4.94 | 11.32 |
| Change against $4.66 (%) | (40) | 6 | 143 |
| Implied annual return (%) | (15.5) | 2.0 | 34.4 |
| Description | No PPA, cash runs down | Late PPA, first NPM revenue | TVA PPA and OEM agreement signed |
| Revenue CAGR \ EV/Sales | 2x | 3x | 5x | 8x |
|---|---|---|---|---|
| 100% | $2.60 | $2.64 | $2.73 | $2.85 |
| 200% | $2.80 | $2.94 | $3.23 | $3.66 |
| 350% | $3.48 | $3.96 | $4.93 | $6.37 |
| 500% | $4.80 | $5.94 | $8.23 | $11.66 |
| 720% | $8.35 | $11.27 | $17.10 | $25.85 |
This analysis is for information only and is not financial advice. It is derived from public SEC filings retrieved via sec-api.io and is not a publication of the U.S. Securities and Exchange Commission. Scenario values are model outputs under stated assumptions and are not forecasts. Data as of 15 Nov 2026, with filings to 13 Nov 2026 and the share price at the 13 Nov 2026 close.
All company and peer figures are read from SEC filings retrieved through the sec-api.io MCP server. Share prices are regular session closes as dated in the text.
| Form | Period | Filed | Accession number |
|---|---|---|---|
| 8-K Ex 99.1 (Q3 2026 results) | 30 Sep 2026 | 5 Nov 2026 | 0001822966-26-000089 |
| 10-Q Q3 2026 | 30 Sep 2026 | 5 Nov 2026 | 0001822966-26-000091 |
| 10-Q Q2 2026 | 30 Jun 2026 | 5 Aug 2026 | 0001822966-26-000085 |
| 10-Q Q1 2026 | 31 Mar 2026 | 7 May 2026 | 0001822966-26-000054 |
| 10-K FY2025 | 31 Dec 2025 | 26 Feb 2026 | 0001822966-26-000018 |
| 10-K FY2024 | 31 Dec 2024 | 3 Mar 2025 | 0001822966-25-000024 |
| 10-K FY2023 | 31 Dec 2023 | 15 Mar 2024 | 0001822966-24-000039 |
| 10-K FY2022 | 31 Dec 2022 | 15 Mar 2023 | 0001822966-23-000059 |
| 10-Q Q3 2025 | 30 Sep 2025 | 6 Nov 2025 | 0001822966-25-000175 |
| 10-Q Q2 2025 | 30 Jun 2025 | 7 Aug 2025 | 0001822966-25-000133 |
| 10-Q Q1 2025 | 31 Mar 2025 | 12 May 2025 | 0001822966-25-000088 |
| DEF 14A 2026 | 15 Apr 2026 | 15 Apr 2026 | 0001822966-26-000042 |
| SC 13D/A no. 7 (Fluor) | 13 Feb 2026 | 17 Feb 2026 | 0001124198-26-000015 |
| SC 13D/A no. 6 (Fluor) | 6 Nov 2025 | 10 Nov 2025 | 0001124198-25-000094 |
| Schedule 13G/A (Van Eck) | 30 Sep 2026 | 13 Nov 2026 | 0000869178-26-000111 |
| Schedule 13G (Vanguard Capital Management) | 30 Sep 2026 | 30 Oct 2026 | 0002100119-26-001663 |
| Schedule 13G (BlackRock) | 30 Jun 2026 | 29 Jul 2026 | 0002012383-26-002835 |
| Form 4 (Fluor, 13.5m shares) | 21 Apr 2026 | 23 Apr 2026 | 0001124198-26-000049 |
| Form 4 (Fluor, 71.0m shares) | 13 Feb 2026 | 17 Feb 2026 | 0001124198-26-000016 |
| Company | Form | Filed | Accession number |
|---|---|---|---|
| NuScale Power | 8-K (Items 5.02, 5.03, 8.01) | 17 Nov 2025 | 0001822966-25-000179 |
| NuScale Power | 8-K (Items 5.03, 5.07) | 17 Dec 2025 | 0001822966-25-000186 |
| NuScale Power | 8-K (Items 7.01) | 27 Jan 2026 | 0001822966-26-000007 |
| NuScale Power | 8-K (Items 2.02) | 26 Feb 2026 | 0001822966-26-000016 |
| NuScale Power | 8-K (Items 1.01, 1.02) | 26 Feb 2026 | 0001822966-26-000019 |
| NuScale Power | 8-K (Items 7.01) | 8 Apr 2026 | 0001822966-26-000038 |
| NuScale Power | 8-K (Items 2.02) | 7 May 2026 | 0001822966-26-000052 |
| NuScale Power | 8-K (Items 5.07) | 2 Jun 2026 | 0001822966-26-000058 |
| NuScale Power | 8-K (Items 2.02) | 5 Aug 2026 | 0001822966-26-000086 |
| NuScale Power | 8-K (Items 1.01) | 11 Aug 2026 | 0001104659-26-094073 |
| NuScale Power | 8-K (Items 2.02) | 5 Nov 2026 | 0001822966-26-000089 |
| BWX Technologies | 10-K FY2025 | 23 Feb 2026 | 0001486957-26-000007 |
| BWX Technologies | 10-Q Q3 2026 | 2 Nov 2026 | 0001486957-26-000051 |
| GE Vernova | 10-K FY2025 | 29 Jan 2026 | 0001996810-26-000015 |
| GE Vernova | 10-Q Q3 2026 | 28 Oct 2026 | 0001996810-26-000163 |
| NANO Nuclear Energy | 10-K FY2025 (Sep 2025) | 18 Dec 2025 | 0001493152-25-028285 |
| NANO Nuclear Energy | 10-Q Jun 2026 quarter | 12 Aug 2026 | 0001493152-26-037345 |
| Oklo | 10-K FY2025 | 17 Mar 2026 | 0001628280-26-018698 |
| Oklo | 10-Q Q3 2026 | 6 Nov 2026 | 0001628280-26-071319 |
| Filed | Exhibit | Document | Content |
|---|---|---|---|
| 17 Nov 2025 | Ex 3.1 | Amended and Restated Bylaws | Article V names the Chief Accounting Officer as an officer; Controller no longer required to be the Chief Accounting Officer. |
| 17 Nov 2025 | Ex 10.1 | Deferred Compensation Plan for Non Employee Directors (22 Nov 2025) | Directors may defer cash retainers paid in Class A shares and RSU awards; Deferral runs to separation from service, change in control, death or disability. |
| 17 Dec 2025 | Ex 3.1 | Certificate of Amendment | Authorized Class A shares raised from 332,000,000 to 662,000,000; Approved by 184.5m votes for and 28.0m against on 16 Dec 2025. |
| 27 Jan 2026 | Ex 99.1 | Call announcement, Q4 and FY2025 | Results call set for 26 Feb 2026 at 5:00 pm ET. |
| 26 Feb 2026 | Ex 99.1 | Q4 and FY2025 results release | FY2025 revenue $31.5m against $37.0m; cost of sales $20.0m against $4.9m; G&A $609.8m incl. Milestone Contribution 1 of $507.4m; cash and investments $1.3bn; 39.3m ATM shares for $750.0m gross in Q4 2025. |
| 26 Feb 2026 | Ex 1.1 | Sales Agreement, $1.0bn ATM program | Agents UBS, B. Riley, Canaccord and Tuohy Brothers; commission up to 2%; Program completed in Jun 2026: 89.7m shares for $1.0bn gross (10-Q). |
| 26 Feb 2026 | Ex 5.1 | Legal opinion (O'Melveny & Myers) | Validity of shares issued under the Sales Agreement. |
| 26 Feb 2026 | Ex 23.1 | Consent of counsel | Consent to the opinion filed as Ex 5.1. |
| 8 Apr 2026 | Ex 99.1 | Call announcement, Q1 2026 | Results call set for 7 May 2026 at 5:00 pm ET. |
| 7 May 2026 | Ex 99.1 | Q1 2026 results release | Revenue $0.6m against $13.4m; net loss $46.7m; liquidity $1.0bn; Nuclearelectrica shareholders approved the next RoPower phase; Framatome partnership expanded. |
| 5 Aug 2026 | Ex 99.1 | Q2 2026 results release | Revenue $0.1m against $8.1m; R&D +$6.6m; liquidity $1.9bn; Paragon contract for the HIPS final design; supply chain of over 60 partners and over 30 agreements. |
| 11 Aug 2026 | Ex 1.1 | Sales Agreement, $750m ATM program | Agents UBS, B. Riley, Canaccord, Craig‑Hallum, Texas Capital Securities and Tuohy Brothers; commission up to 2%; No shares sold in Q3 2026 (10-Q). |
| 11 Aug 2026 | Ex 5.1 | Legal opinion (O'Melveny & Myers) | Validity of shares issued under the Sales Agreement. |
| 5 Nov 2026 | Ex 99.1 | Q3 2026 results release | Revenue $0.3m against $8.2m; G&A down $491.3m; investment income $19.1m (+$13.4m); Doosan contract for the upper reactor coolant system; cash and investments $1.9bn. |